Biggest changeThe following table presents a reconciliation of adjusted EBITDA to net loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2020 2021 2022 Net loss $ (55,422) $ (128,565) $ (465,264) Plus: Interest expense, net 3,048 12,563 2,556 Depreciation and amortization 7,826 29,871 37,544 Stock-based compensation expense 32,396 50,264 44,686 Acquisition and integration costs (benefits) — 24,372 (2,874) Change in fair value of contingent consideration — 1,374 (128,174) Foreign currency (gain) loss (1,549) 1,267 6,376 Impairment of goodwill and intangible assets — — 453,288 Restructuring and reduction of force 1,323 713 8,139 Income tax benefit — (7,864) (1,446) Deferred implementation costs 4,598 3,785 — Adjusted EBITDA $ (7,780) $ (12,220) $ (45,169) 48 Table of Contents The following table presents a reconciliation of adjusted EBITDA to adjusted contribution, the most directly comparable segment income measure, for each of the periods indicated (in thousands): Year Ended December 31, 2020 Cardlytics Platform Bridg Platform Consolidated Adjusted contribution $ 82,182 $ — $ 82,182 Minus: Delivery costs 14,310 — 14,310 Sales and marketing expense 45,307 — 45,307 Research and development expense 17,532 — 17,532 General and administration expense 46,532 — 46,532 Stock-based compensation expense (32,396) — (32,396) Restructuring and reduction of force (1,323) — (1,323) Adjusted EBITDA $ (7,780) $ — $ (7,780) Year Ended December 31, 2021 Cardlytics Platform Bridg Platform Consolidated Adjusted contribution $ 121,675 $ 7,953 $ 129,628 Minus: Delivery costs 18,170 4,333 22,503 Sales and marketing expense 62,771 3,225 65,996 Research and development expense 35,393 2,711 38,104 General and administration expense 63,379 2,843 66,222 Stock-based compensation expense (47,223) (3,041) (50,264) Restructuring and reduction of force (713) — (713) Adjusted EBITDA $ (10,102) $ (2,118) $ (12,220) Year Ended December 31, 2022 Cardlytics Platform Bridg Platform Consolidated Adjusted contribution $ 122,981 $ 20,053 $ 143,034 Minus: Delivery costs 24,112 6,290 30,402 Sales and marketing expense 67,830 6,915 74,745 Research and development expense 47,579 6,856 54,435 General and administration expense 79,069 2,377 81,446 Stock-based compensation expense (43,490) (1,196) (44,686) Restructuring and reduction of force (8,139) — (8,139) Adjusted EBITDA $ (43,980) $ (1,189) $ (45,169) 49 Table of Contents Components of Results of Operations Revenue We sell our Cardlytics platform solution by entering into agreements directly with marketers or their marketing agencies, generally through the execution of insertion orders.
Biggest change(2) Deferred implementation costs is excluded from Adjusted Partner Share and other third-party costs as follows (in thousands): Year Ended December 31, 2021 Cardlytics Platform Bridg Platform Consolidated Partner Share and other third-party costs $ 140,864 $ 409 $ 141,273 Minus: Deferred implementation costs 3,785 — 3,785 Adjusted Partner Share and other third-party costs $ 137,079 $ 409 $ 137,488 46 Adjusted EBITDA The following table presents a reconciliation of Adjusted EBITDA to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Net Loss $ (134,702) $ (465,264) $ (128,565) Plus: Interest expense, net 2,336 2,556 12,563 Depreciation and amortization 26,460 37,544 29,871 Stock-based compensation expense 40,980 44,686 50,264 Acquisition, integration and divestiture (benefits) costs (6,313) (2,874) 24,372 Change in fair value of contingent consideration 1,246 (128,174) 1,374 Foreign currency (gain) loss (3,304) 6,376 1,267 Impairment of goodwill and intangible assets 70,518 453,288 — Loss on divestiture 6,550 — — Restructuring and reduction of force — 8,139 713 Income tax benefit — (1,446) (7,864) Deferred implementation costs — — 3,785 Adjusted EBITDA $ 3,771 $ (45,169) $ (12,220) 47 The following table presents a reconciliation of Adjusted EBITDA to Adjusted Contribution, the most directly comparable segment income measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Consolidated Adjusted Contribution $ 158,626 $ 143,034 $ 129,628 Minus: Delivery costs 28,248 30,402 22,503 Sales and marketing expense 57,425 74,745 65,996 Research and development expense 51,352 54,435 38,104 General and administration expense 58,810 81,446 66,222 Stock-based compensation expense (40,980) (44,686) (50,264) Restructuring and reduction of force — (8,139) (713) Adjusted EBITDA $ 3,771 $ (45,169) $ (12,220) Cardlytics platform Adjusted Contribution $ 135,518 $ 122,981 $ 121,675 Minus: Delivery costs 21,447 24,112 18,170 Sales and marketing expense 48,671 67,830 62,771 Research and development expense 45,746 47,579 35,393 General and administration expense 56,542 79,069 63,379 Stock-based compensation expense (37,782) (43,490) (47,223) Restructuring and reduction of force — (8,139) (713) Adjusted EBITDA $ 894 $ (43,980) $ (10,102) Bridg platform Adjusted Contribution $ 23,108 $ 20,053 $ 7,953 Minus: Delivery costs 6,801 6,290 4,333 Sales and marketing expense 8,754 6,915 3,225 Research and development expense 5,606 6,856 2,711 General and administration expense 2,268 2,377 2,843 Stock-based compensation expense (3,198) (1,196) (3,041) Restructuring and reduction of force — — — Adjusted EBITDA $ 2,877 $ (1,189) $ (2,118) 48 Adjusted Net Loss The following table presents a reconciliation of Adjusted Net Loss to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2023 2022 2021 Net Loss $ (134,702) $ (465,264) $ (128,565) Plus: Stock-based compensation expense 40,980 44,686 50,264 Foreign currency (gain) loss (3,304) 6,376 1,267 Acquisition, integration and divestiture (benefits) costs (6,313) (2,874) 24,372 Amortization of acquired intangibles 13,589 25,019 19,712 Change in fair value of contingent consideration 1,246 (128,174) 1,374 Impairment of goodwill and intangible assets 70,518 453,288 — Loss on divestiture 6,550 — — Restructuring and reduction of force — 8,139 713 Income tax benefit — (1,446) (7,864) Adjusted Net Loss $ (11,436) $ (60,250) $ (38,727) Weighted-average number of shares of common stock used in computing Adjusted net loss per share: Weighted-average common shares outstanding, diluted 36,488 33,419 32,202 Adjusted weighted-average common shares outstanding, diluted 36,488 33,419 32,202 Adjusted Net Loss per share attributable to common stockholders, diluted $ (0.31) $ (1.80) $ (1.20) Free Cash Flow The following is a reconciliation of free cash flow to the most comparable GAAP measure, net cash used in operating activities (in thousands): Year Ended December 31, 2023 2022 2021 Net cash used in operating activities $ (185) $ (53,904) $ (38,523) Plus: Acquisition of property and equipment (667) (1,171) (3,108) Acquisition of patents — (175) (133) Capitalized software development costs (11,725) (12,140) (9,323) Free Cash Flow $ (12,577) $ (67,390) $ (51,087) Components of Results of Operations Revenue We sell our Cardlytics platform solution by entering into agreements directly with marketers or their marketing agencies, generally through the execution of insertion orders.